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Introduction
Parasitic diseases are a major obstacle to human
health and economic development in many parts of
the world, and cause high rates of mortality and mor-
bidity. In particular protozoa of the order Kinetoplas-
tida are a significant problem. These parasites give
rise to Chagas’ disease (caused by Trypanosoma
cruzi), sleeping sickness (Trypanosoma brucei spp.),
and leishmaniasis (Leishmania spp.).
[1] These infections
afflict between 28 and 30 million people, cause in
excess of 120,000 deaths a year, and contribute to
4.4 million years of disability-adjusted life.
[1] At pres-
ent therapies against these diseases are poor with
treatment failure being common due to widespread
resistance and severe side effects.
[1] Thus there is a need for
the development of new, efficient and safe drugs for the treat-
ment of these diseases.
A promising target for the design of new drugs involves
thiol metabolism in these protozoa, where redox balance is
maintained uniquely by the dithiol trypanothione (T[SH]2 or
N
1,N
8-bis[glutathionyl]spermidine).
[2] Trypanothione counteracts
environmental oxidative stress through a variety of enzymatic
and nonenzymatic reactions, and has been implicated in ac-
quired resistance to chemotherapeutic agents.
[3,4] The majority
of these protective reactions oxidize T[SH]2 to trypanothione
disulfide (T[S]2), which is recycled back to T[SH]2 by trypano-
thione reductase (TryR; EC 1.8.1.12), an NADPH-dependent di-
sulfide oxidoreductase (Scheme 1). TryR is thought to be the
central enzyme in the redox metabolism of these protozoans,
being the sole route of reducing equivalents from the NADP
+/
NADPH couple to thiol-containing species.
[5] The importance of
trypanothione metabolism is reflected in the fact that a
number of currently used antiprotozoan compounds work, at
least in part, by affecting trypanothione metabolism; the mela-
mino-arsenicals bind to trypanothione and possibly also TryR;
[6]
difluoromethylornithine (DFMO) inhibits the biosynthesis of
spermidine, a constituent of trypanothione;
[7] and antimonials
form complexes with trypanothione and inhibit TryR.
[8]
Genetic validation (RNAi and knockout studies) has indicated
the importance of TryR to parasite survival.
[9–11] In contrast, in
the mammalian host, trypanothione metabolism is absent and
glutathione is the primary low-molecular-mass thiol, with the
enzyme glutathione reductase (GR) performing the role of re-
ducing glutathione to glutathione disulfide. Despite trypanoso-
matid TryR and human GR both showing 40% sequence
identity,
[12] each enzyme is highly specific for its respective di-
sulfide substrate, where charge is a major discriminating
factor.
[13,14] The significant structural differences between TryR
and GR suggests that it should be possible to design selective
inhibitors of TryR. Indeed, there are many cases of selective
Trypanothione reductase (TryR) is a key validated enzyme in
the trypanothione-based redox metabolism of pathogenic try-
panosomes and leishmania parasites. This system is absent in
humans, being replaced with glutathione and glutathione re-
ductase, and as such offers a target for selective inhibition. As
part of a program to discover antiparasitic drugs, the
LOPAC1280 library of 1266 compounds was screened against
TryR and the top hits evaluated against glutathione reductase
and T. brucei parasites. The top hits included a number of
known tricyclic neuroleptic drugs along with other new scaf-
folds for TryR. Three novel druglike hits were identified and
SAR studies on one of these using information from the tricy-
clic neuroleptic agents led to the discovery of a competitive in-
hibitor (Ki=330 nm) with an improved potency against
T. brucei (EC50=775 nm).
Scheme 1. Reaction carried out by trypanothione reductase (TryR).
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weight to TryR as a potential drug target.
In recent years several different classes of compounds have
been reported as TryR inhibitors.
[15–52] However, with the excep-
tion of the antimonials,
[8] none of these compounds are cur-
rently used clinically against trypanosomiases or leishmaniases.
To address the need for new compounds and new compound
classes, we initiated a screening of 1266 pharmacologically
active compounds from the Sigma–Aldrich LOPAC1280 library.
These compounds were screened against TryR, and the top
hits counter-screened against GR and live T. brucei parasites,
yielding the IC50 values, selectivity for TryR over GR and anti-
parasitic activity. We also investigated the druglikeness of the
molecules.
[53] Based on these data we synthesised a number of
analogues and fragments of one of the most promising hits:
1-(2-(benzhydryloxy)ethyl)-4-(3-phenylpropyl)piperazine (M)
based on its similarity to the known tricyclic (neuroleptic) in-
hibitor of TryR, prochlorperazine (K) (Figure 1). Kinetic testing
of these compounds revealed a fivefold improvement over M
for one of them. Incorporating
these improvements to prochlor-
perazine itself produced a com-
petitive inhibitor with a tenfold
improvement in IC50 value, with
a Ki value in the submicromolar
region. Subsequent testing on
live T. brucei parasites showed
most of the compounds to be
more active against the parasites
than against the purified
enzyme. The compound with
the highest EC50 value was com-
pound 9.
Results and Discussion
Screening
The LOPAC1280 library, compris-
ing 1266 compounds, was initial-
ly screened in duplicate at
100 mm yielding 170 active com-
pounds with inhibition >50%
for TryR. Hits were re-tested at
10 mm and the 35 most potent
compounds (inhibition>77%)
were assayed to determine IC50
values against TryR. The 22 most
potent molecules also had their
IC50 values determined against
human GR and were assayed for
trypanocidal activity in vitro.
The most potent TryR inhibitor
(aurin tricarboxylic acid; ACHTUNGTRENNUNG3-(bis(3-
carboxy-4-hydroxyphenyl)methy-
lene)-6-oxocyclohexa-1,4-diene-
carboxylic acid) had an IC50 value
of 176 nm, but was not selective for TryR over GR and showed
the weakest trypanocidal activity in the series. Results for the
top 13 inhibitors of TryR, which also showed inhibition of
T. brucei with EC50 values <15 mm, are summarised in Table 1
ranked in order of inhibition of TryR (see Figure 2 for typical
IC50 and EC50 determinations). Of these, four compounds (A–D)
had IC50 values less than clomipramine (E;I C 50=3.8 mm), a
known tricyclic (neuroleptic) competitive inhibitor of TryR,
which happened to be present in the LOPAC1280 library.
[15,30]
The IC50 value for clomipramine E agrees well with the IC50 de-
termined using our commercial standard (2.7 mm) demonstrat-
ing the robustness of the assay. When tested against the para-
site, nine compounds had EC50 values less than clomipramine.
The most potent trypanocidal compound A had an EC50 value
of 1.5 nm, which is lower than the standard drug pentamidine
(EC50=18 nm).
[54] However, it was disappointing to discover
that compound A is an organo-mercurial, a nonspecific thiol-al-
kylating agent and therefore totally unsuitable as a lead.
Indeed, analysis revealed that many of the best hits by IC50
Figure 1. Structures and trivial names of screening hits (see Table 1).
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[53] and the most druglike hits
were from the already known tricyclic (neuroleptic) class of in-
hibitors.
[15,30] Of the thirteen most active compounds in Table 1,
nine have EC50 values against the parasite lower than their IC50
values against the target enzyme (i.e. ratio<1), which suggests
that these compounds may have additional off-target effects
(e.g. A, B, C, G and I have thiol-reactive groups and show the
lowest selectivity index between TryR and GR), or may be se-
lectively concentrated/metabolically activated in the parasite,
or a combination of these.
Most compounds show specificity towards TryR with only
two displaying preferential inhibition of GR (ratio GR IC50/TryR
IC50 <1) and two displaying poor selectivity (ratio GR IC50/TryR
IC50>1 and <3). Selectivity (SI) towards TryR marked as > in
Table 1 indicates that these compounds showed less than 20%
inhibition of human GR at a concentration of 100 mm so that
an accurate IC50 could not be obtained.
Interestingly, of the nine compounds in Table 1 that are
greater than ninefold selective for the parasite enzyme, five
belong to the tricyclic (neuroleptic) class of compounds.
[3] This
is significant given that the target product profile for African
sleeping sickness is for a compound that is active against late
stage CNS infections, which could replace melarsoprol, an ar-
senical that causes fatal encephalopathy in about 5% of pa-
tients.
[1] However, the archetypical drug of this class, clomipra-
mine, has already been shown to be of marginal value as a try-
panocidal drug lead.
[33]
Another key filter for progression of compounds is druglike-
ness. This is usually investigated by calculating the physico-
chemical properties of a compound to ensure that they are ap-
propriate to permit the inhibitor to reach the molecular target
in a whole organism. For orally bioavailable compounds, Lipin-
ski’s rule of five is used to assess this.
[55] The concept of drug-
likeness can be extended further to ensure that there are no
chemically or metabolically reactive functionalities, although
this often requires experimental determination. For HAT, the
desired compound must have at least some degree of blood–
brain barrier permeability in order to treat late-stage infections,
which imposes additional constraints (ideally a lower molecular
weight and polar surface area). As an approach to measure
druglikeness, compounds were assessed using the molsoft
drug-scoring system (www.molsoft.com). Of the top three hits
as ranked by EC50 value against T. brucei, the druglikeness of A,
C and G is poor, partly because of the chemical reactivity of
these molecules. Likewise, ebselen (B) was not deemed suita-
ble for further development, partly due to the fact it contained
selenium, but also due to its reported reaction with thiol
groups and NADPH in the presence of a thiol group containing
enzyme,
[56,57] suggesting that it might be a promiscuous inhibi-
tor.
In summary, a number of criteria were applied to select hits
from the initial screen: potency and selectivity against both
enzyme and parasite; druglikeness, particularly the probability
of blood–brain barrier permeability; and chemical tractability.
This gave three compounds that we decided to investigate fur-
ther: GBR-12935 (M), BTCP (D), and indatraline (J). (Substantial
Table 1. Top 13 results from EC50 and IC50 value determinations from a
LOPAC1280 screen ranked in order of IC50 potency against TryR.
Compd T. brucei
EC50 [mm]
TryR
IC50 [mm]
GR
IC50 [mm]
Tb EC50/
TryR IC50
SI
[a] Drug
Score
[b]
A 0.00154 0.251 0.00501 0.00614 0.0200 –
B 2.97 1.36 21.5 2.18 15.8 –
C 0.139 2.21 3.37 0.0629 1.52 0.07
D 13.6 3.69 >100 4.39 >32.3 1.35
E 5.04 3.80
[c] >100 1.33 >26.3 1.29
F 7.67 4.88 >100 1.57 >20.5 1.79
G 1.52 4.94 12.5 0.308 2.53 1.52
H 4.21 6.32 >100 0.666 >15.8 1.42
I 2.89 6.89 4.56 0.419 0.662 0.13
J 1.97 7.26 >100 0.271 >13.8 0.65
K 4.48 7.46 >100 0.601 >13.4 1.83
L 1.73 7.53
[d] >100 0.230 >13.3 1.58
M 9.3 10.9 >100 0.853 >9.17 0.57
[a] Selectivity index: ratio of GR IC50 over TryR IC50. [b] Druglikeness scores
calculated using the High Speed Molecular Properties calculator from
Molsoft.
[53] Most known drugs have a score > 0 and the optimum score
value is 1.0. [c] Ki=6.50.6 Dixon plot 20 mm HEPES pH 7.25, 0.15 mm
KCl.
[15] [d] Ki=21.91.7 Dixon plot 20 mm HEPES pH 7.25, 0.15 mm KCl.
[15]
Figure 2. Specimen data showing a) IC50 determination for compound D
against TryR (IC50=3.690.06 mm) and b) EC50 determination of compound I
against T. brucei parasites (EC50=2.680.15 nm). Experimental details are de-
scribed in the Experimental Section. The curves show the average value of
three independent measurements (*) and the best fit to a nonlinear four-
parameter equation (c).
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as potential antitrypanosomals.
[14,15,23,29,30,39]) Herein, we de-
scribe the further study of compound M and derivatives as
ACHTUNGTRENNUNGpotential antiparasitic agents. Further data based on BTCP (D),
and indatraline (J) will be described in due course.
Chemistry
A limited chemistry programme was carried out around com-
pound M (compounds 3–9), in particular to see if there was
any cross-over with this scaffold and that of clomipramine (E)
and the phenothiazines (F, H, K, L). Thus, the diphenylmethane
moiety was cyclised to the corresponding dibenzosuberol and
phenothiazine scaffolds (6–8 and 9, respectively). Also the
effect of the phenylpropyl substituent was investigated (cf. 6
and 7).
The compounds 6, 7 and 8 (Scheme 2) were prepared by
nucleophilic substitution reactions between the intermediate
5-(2-chloroethoxy-)-10,11-dihydro-5H-dibenzoACHTUNGTRENNUNG[a,d]cycloheptene
(4) and the appropriate substituted piperazines in yields of be-
tween 33 and 41%.
[58] Compound 5 was prepared by nucleo-
philic substitution between the intermediate (2-chloroethoxy)-
diphenylmethane 3 and anhydrous piperazine (Scheme 2) in a
yield of 53%.
[59] Intermediate compound 4 was formed by re-
action between dibenzosuberol and 2-chloroethanol in a yield
of 70%. Similarly, compound 3 was formed by reaction of
benzhydrol and 2-chloroethanol in a yield of 82%.
[58] The sub-
stituted piperazine, 1-(3-phenylpropyl)piperazine, was formed
by a nucleophilic substitution reaction between anhydrous pi-
perazine and 1-bromo-3-phenylpropane in a yield of 23%.
The synthesis of 2-chloro-10-(3-(4-(3-phenylpropyl)piperazin-
1-yl)propyl)-10H-phenothiazine (9, Scheme 3) was achieved in
two steps by nucleophilic substitution between 2-chloro-10H-
phenothiazine and 1,3-dibromopropane to give 10-(3-bromo-
propyl)-2-chloro-10H-phenothiazine.
[60] Further reaction, with-
out prior purification, with 1-(3-phenylpropyl)piperazine afford-
ed 9 in an overall yield of 5%.
Enzymatic assays
Cyclisation of the diphenyl derivative M to the tricyclic scaf-
folds based on clomipramine (E) or chlorpromazine (H) gave
an improvement of activity against TryR (7,I C 50=1.9 mm; 9,
IC50=0.75 mm) compared to M (IC50=10.9 mm) (Table 2). This
indicates that rigidifying the diphenylmethane moiety as a tri-
cyclic improves target binding.
The presence of the phenylpropyl moiety increased activity
significantly against the enzyme (cf. 6 and 7; 5 and M), sug-
gesting that the phenylpropyl moiety has an interaction in the
binding site, as has been previously seen in the polyamine
class of inhibitors.
[19] The increase in binding potency of the
phenylpropyl group can also been seen in the increase in po-
tency when added to the clomipramine (E) or chlorpromazine
(H) scaffolds. In particular the replacement of the N-methyl
group in prochlorperazine (K) by a 3-phenylpropyl moiety
caused a tenfold decrease in the IC50 value for this compound
(cf. K,I C 50=7.46 mm and 9,I C 50=0.750 mm), highlighting the
important role played by this moiety. Addition of this moiety
Table 2. Results of IC50 and EC50 value determinations of compounds re-
lated to the parent molecule M (GBR-12935).
Compd
[a] TryR
IC50 [mm]
GR
IC50 [mm]
T. brucei
EC50 [mm]
1 >100 ND
[b] >100
[c]
2 >100 ND 51.31.6
3 82.915.5 ND 32.11.01
4 29.71.9 ND 27.90.5
5 48.74.0 ND 13.50.7
6 51.57.9 ND 9.321.12
7 1.940.03 >100 3.500.27
8 26.93.7 >100 2.170.12
9 0.750.06 >100 0.7750.031
1-(3-phenylpropyl)pipera-
zine
34.53.8 ND ND
1-propylbenzene >100 ND ND
3-phenylpropylamine >100 ND ND
[a] Compounds synthesised in this paper are shown as their compound
number, other compounds names are given in full. [b] ND: not deter-
mined. [c] Values shown as >100 mm showed less than 20% inhibition at
a concentration of 100 mm.
Scheme 3. Synthesis of 2-chloro-10-(3-(4-(3-phenylpropyl)piperazin-1-yl)prop-
yl)-10H-phenothiazine (9). Reagents and conditions: a) BrCH2CH2CH2Br, KOH,
DMF; b) 1-(3-phenylpropyl)piperazine, K2CO3, MePh, D.
Scheme 2. Reagents and conditions: a) 2-chloroethanol, pTSA, MePh, D;
b) substituted piperazine, K2CO3, MePh, D.
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(IC50>100 mm). The successful synthesis of an improved submi-
cromolar inhibitor of TryR led us to determine the Ki value and
the mode of inhibition of compound 9, revealing linear com-
petitive inhibition with a Ki value of 33119 nm (Figure 3).
In contrast to compound 7, compound 8 showed a decrease
in potency against TryR compared with M (M,I C 50=10.9 mm;
8,I C 50=26.9 mm, Table 2) suggesting that the phenylpropyl
chain is better at binding in this position than the 1-cinnamyl
chain.
Compound M can be subdivided into two moieties: the di-
phenylmethane or tricyclic moiety and the phenylpropyl
moiety. Both of these individual fragments of compound M
showed some activity on their own, albeit at a reduced level.
Thus 1-(3-phenylpropyl)piperazine gave an IC50 value of
34.5 mm against TryR (Table 2), which again points to a phenyl-
propylpiperazine pocket being present in the active site. The
specificity of this phenylpropylpiperazine pocket is illustrated
by the fact than piperazine itself, propylbenzene, 3-phenylpro-
pylamine and 1-bromo-3-phenylpropane only bind very weakly
to the enzyme (IC50>100 mm). Similarly, the diphenylmethyl
and dibenzosuberyl containing compounds (3 and 4) both
showed weak activity (IC50=82.9 and 29.7 mm, respectively).
Again, the stronger binding of compound 4 compared with 3
suggests the greater ability of the more rigid ring system to
bind in the tricyclic pocket of TryR.
[25,39]
Cell-based assays on compounds 1–9
The EC50 values of compounds 1–9 were determined in the
same manner as in the initial screening, and seven of these
were found to be lower than the corresponding IC50 values
against TryR. This suggests, as was found in the initial screen-
ings, that once again these compounds have additional off-
target activity or may be selectively concentrated/metabolically
activated or a combination of these. Nonetheless, when the
IC50 values against TryR were plotted against the EC50 values
against live T. brucei parasites, the coefficient of determination
(R
2) was 0.72, suggesting a reasonable correlation between
enzyme and cell activity. The lowest EC50 value was obtained
for compound 9 (EC50=0.7750.031 mm), which is the third
lowest measured in this study, and the best for a compound
considered to be druglike (compound 9, drug score=0.57).
[53]
This EC50 value represents a 12-fold improvement from the
model compound M, which itself is 2.65 times less potent than
the ring-joined model compound 7, proving its relationship to
the tricyclic neuroleptic class of inhibitors, and in part confirm-
ing the principal of the phenylpropyl moiety improving effica-
cy.
Conclusions
The screening of the LOPAC1280 library against TryR and re-
testing of hits against human GR and T. brucei parasites re-
vealed three new classes of TryR inhibitors J, D and M worthy
of further development. The screening also revealed that there
is no clear relationship between IC50 and EC50 values for the 22
inhibitors where these were measured, revealing that off-
target effects, selective concentration/metabolic activation, or
a combination of these factors affect some of these inhibitors.
The inhibitor M has been shown to mimic the tricyclic neu-
roleptic class of inhibitor, where replacement of the diphenyl-
methane with a 10,11-dihydro-5H-dibenzoACHTUNGTRENNUNG[a,d]cycloheptene
ring system caused a fivefold decrease in IC50 value of the in-
hibitor, placing it in the same potency range as the tricyclic
class of inhibitors. The information that the active site of the
inhibitor may possess a phenylpropyl pocket near where the
tricyclic class of inhibitor binds resulted in the synthesis of a
prochlorperazine congener with a tenfold decrease in IC50
value. In the cases where improved inhibitors have been syn-
thesised (7 and 9) lack of activity against human GR (IC50>
100 mm) has been retained.
Experimental Section
Overview of screening
Compounds were initially screened at a concentration of 100 mm in
96-well plates. Positive (1% v/v DMSO) and negative (100 mm clo-
mipramine) controls were included on each plate. Plates were as-
sayed in duplicate. Compounds exhibiting >50% inhibition at
100 mm were re-screened at a concentration of 10 mm in duplicate.
The IC50 values were determined in triplicate for the top 37 most
potent compounds, and the 22 most potent of these were assayed
in triplicate against T. brucei in vitro to determine the EC50 values.
In addition, the same 22 compounds were screened against
human GR and their IC50 values determined whenever possible.
Figure 3. Determination of the inhibition constant (Ki) for compound 9.A
Lineweaver–Burke plot of compound 9 with recombinant TryR from T. cruzi.
Ki was calculated to be 33119 nm. Points shown are the mean of three
measurements at six different substrate concentrations, the lines shown are
the least squares fits to the points weighted to one over the standard devia-
tion squared. The concentration of compound 9 was varied (*,0 ;!, 188; *,
375; &, 750 nm) with the concentration of NADPH being saturating
(>10 times Km).
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The assay is based on the colorimetric reduction of 5,5’-dithiobis-
(2-nitrobenzoic acid) (DTNB) by T[SH]2.
[37] The assay mixture consist-
ed of: 40 mm HEPES pH 7.4, 1 mm EDTA, 6.0 mm T[S]2,5 0mm DTNB,
2m Um L
1 TryR and 150 mm NADPH. Initial screens at 100 mm were
completed in duplicate in 96-well plates with DMSO (1% v/v, final
concentration) as a positive control (column 1) and clomipramine
(100 mm) as a negative control (column 12). An amount of inhibitor
(1.8 mL, 10 mm stock in DMSO) was added into each of the wells
(100 mm final concentration) and to this was added 158.2 mL of re-
agents (enzyme+trypanothione+DTNB in assay buffer) and finally
20 mL of NADPH solution to start the assay. Absorbance at 412 nm
was monitored at 258C for 15 min using a SpectraMax 340PC (Mo-
lecular Devices) plate reader. The data was inspected for linearity
and the relative percentage inhibitions were calculated from the
following equation: Inhibition=(average velocity of inhibitor
wells)/(average velocity of 1% DMSO wells)(average velocity of
clomipramine wells) 100.
IC50 values were determined using 11 serial dilutions. Starting with
12 mL of a 10 mm DMSO solution of the inhibitor, 6 mL was re-
moved and added to another Eppendorf tube containing 6 mLo f
DMSO. The tube was sealed, mixed and then briefly centrifuged to
ensure that the sample was at the bottom of the tube. This proce-
dure was repeated 11 times to produce 12 serial 50% dilutions.
Assays were performed in triplicate as described above. Data were
inspected for linearity and IC50 values determined by nonlinear re-
gression to the following four-parameter equation: y=(range/ACHTUNG-
TRENNUNG(1+x/IC50)
Slope factor)+background. For human GR, essentially the
same procedure as above was used with the assay composition as
follows: 40 mm HEPES pH 7.4, 1 mm EDTA, 15.0 mm glutathione di-
sulphide, 50 mm DTNB, 5 mUmL
1 GR and 150 mm NADPH. The
choice of disulphide concentration in both assays represents
[S]Km.
Cell-based screens
For EC50 value determination against bloodstream T. brucei, test
compounds and the control drug (pentamidine) were dissolved in
DMSO at 10 mm and 0.1 mm concentrations, respectively. Drug sol-
utions (2 mL) were added to the second column (B2–G2) of the 96-
well plate. Aliquots of 100mL HMI-9 medium
[61] containing 1%
DMSO were added to the rest of the wells and 198 mL HMI-9
medium to the second column (B2–G2). Serial drug dilutions were
prepared by withdrawing 100 mL from the second column and
adding into the adjacent column. The process was repeated until
column 10 was reached. A suspension of trypanosomes was pre-
pared at a density of 2 10
3 cellsmL
1 and 100 mL added to each
well except column 1, which received 100 mL HMI-9 instead. Col-
umns 1 and 11 served as a control without trypanosomes and a
control without drug, respectively. Cells were incubated for 3 days
at 378Ci n5 %C O 2, after which 20 mL resazurin (0.5 mm) was
added to each well and plates incubated for a further 4 h before
measuring fluorescence (excitation of 528 nm and emission of
590 nm) on an FLX 800 Fluorescence plate reader (BioTek Instru-
ments). Measurements were obtained on three separate occasions.
Data were processed using the GRAFIT program and fitted to the
following four-parameter equation: y=(range/ACHTUNGTRENNUNG(1+x/EC50)
Slope factor)+
background, to obtain the effective concentration inhibiting
growth by 50% (EC50). The EC50 values reported are the weighted
means, with the values weighted to the inverse squares of their
standard deviations. Pentamidine was used to validate the assay
conditions, giving an EC50 value of 5.40.18 nm, which is lower
than the reported value of 14 nm for the S427 strain of T. brucei.
[54]
The coefficient of variation between assay plates was 3.39%.
Inhibition constant (Ki) determination
The assay solution consisted of: 40 mm HEPES pH 7.4, 1 mm EDTA,
2m Um L
1 TryR and 150 mm NADPH. The rate of NADPH oxidation,
monitored at 340 nm at 258C using a UV-2401PC UV–vis recording
spectrophotometer (Shimadzu Scientific) for six different substrate
concentrations (12.5, 25, 50, 100, 150 and 200 mm trypanothione),
were measured in triplicate over 30 s for four different inhibitor
concentrations (0, 188, 375 and 750 nm). The resulting data was
plotted as a Lineweaver–Burke plot to ascertain the mode of inhib-
ition. The data were fitted using weighted nonlinear regression to
equations describing both competitive and mixed inhibition. The Ki
value given in Figure 3 is the weighted mean of three determina-
tions of Ki values for the three inhibitor concentrations used, fitted
to equation: y=Vmax [Substrate]/Km (1+[Inhibitor]/Ki)+[Substrate]),
describing competitive inhibition.
Chemistry
1H NMR spectra were recorded on a Br cker spectrometer at
500 MHz in CDCl3,
13C NMR spectra were recorded in the same sol-
vent on the same spectrometer at 125 MHz, chemical shifts are re-
ported in ppm. Electrospray mass spectra were recorded on a Mi-
cromass Q-TOF 2 mass spectrometer (Micromass UK).
1-(3-Phenylpropyl)piperazine: A solution of piperazine (10 g,
0.12 mol) and 1-bromo-3-phenylpropane (18.24 mL, 0.12 mol) in
EtOH (25 mL) was heated under reflux for 6 h. The solvent was
evaporated and the residue was partitioned between H2O (125 mL)
and Et2O (125 mL). The aqueous layer was then extracted with Et2O
(5 50 mL) and the combined organic fractions were dried
(MgSO4). The solvent was evaporated to give an oily residue that
was purified by distillation (1728C, 15 mm) to give the title com-
pound as a colourless oil (5.24 g, 23%):
1H NMR (500 MHz, CDCl3):
d=1.85 (q, J=7.1 Hz, 2H), 2.38 (t, J=7.1 Hz, 2H), 2.45 (m, 4H),
2.65 (t, J=10.3 Hz, 2H), 2.85 (t, J=9.1 Hz, 4H), 7.16 (t, J=7.7 Hz,
1H), 7.22 (d, J=7.6 Hz, 1H), 7.26 ppm (t, J=7.7 Hz, 1H);
13C NMR
(125 MHz, CDCl3): d=28.0, 33.5, 53.2, 44.9, 58.0, 125.5, 128.0, 128.9,
138.1 ppm; MS (ES, 50 eV): m/z (%): 204.2 (100), 205.2 (14) [M+H]
+;
HRMS-ES: m/z [M+H]
+ calcd for C13H20N2: 205.16265, found:
205.17254.
General procedure for the synthesis of 2-substituted chloro-
ethanes 3 and 4: A mixture of 1 or 2 (54 mmol) and 2-chloroetha-
nol (3.85 mL, 57 mmol) in toluene (28.8 mL) and pTsOH (0.344 g,
2 mmol) was refluxed for 1 h using a Dean–Stark trap. The cold so-
lution was washed with H2O (15 mL), saturated NaHCO3 solution
(10 mL), H2O (15 mL), dried (MgSO4), filtered and evaporated to
yield the target compounds as white solids. Compounds were
used without further purification.
(2-Chloroethoxy)diphenylmethane (3): (11.66 g, 82%):
1H NMR
(500 MHz, CDCl3): d=3.74 (t, J=6.2 Hz, 2H), 3.80 (t, J=6.2 Hz, 2H),
5.5 (s, 1H), 7.33 (t, J=8.1 Hz, 1H), 7.41 (t, J=8.1 Hz, 1H), 7.45 ppm
(d, J=8.1 Hz, 1H);
13C NMR (125 MHz, CDCl3): d=43.2, 69.2, 84.1,
127.1, 128.0, 129.3, 140.3 ppm; MS (ES, 50 eV): m/z (%): 269.1 (100),
271.1 (32) [M+Na]
+; HRMS-ES: m/z [M+Na]
+ calcd for C15H15ClO:
269.07091, found: 269.07164.
5-(2-Chloroethoxy)-10,11-dihydro-5H-dibenzoACHTUNGTRENNUNG[a,d]cycloheptene
(4): (11.04 g, 70%):
1H NMR (500 MHz, CDCl3): d=3.08 (t, J=
12.9 Hz, 2H), 3.65 (t, J=12.9 Hz, 2H), 3.73 (t, J=6.6 Hz, 2H), 3.79 (t,
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7.6 Hz, 1H), 7.45 ppm (d, J=7.6 Hz, 1H);
13C NMR (125 MHz, CDCl3):
d=32.5, 43.5, 68.0, 69.0, 126.9, 128.2, 128.5, 131.0, 132.9,
136.9 ppm; MS (ES, 50 eV): m/z (%): 295.1 (100), 297.1 (32)
[M+Na]
+; HRMS-ES: m/z [M+Na]
+ calcd for C17H17ClO: 295.08656,
found: 295.08953.
General procedure for synthesis of the N-substituted pipera-
zines (5 and 6): A solution of 3 or 4 (5.42 mmol) in toluene
(1.13 mL) was added to a stirred solution of anhyd piperazine
(1.396 g, 16.2 mmol) and K2CO3 (0.56 g, 4.05 mmol) in toluene
(15.87 mL). The mixture was refluxed for 15 h, cooled to RT and
treated with H2O (25 mL). The organic phase was washed twice
with H2O (2 25 mL) and then extracted with 10% AcOH (2 
20 mL). The combined aqueous acidic solutions were washed with
toluene (3 25 mL). The base was liberated with aqueous NaOH
and extracted with toluene (3 25 mL). The combined organic frac-
tions were washed with H2O, dried (MgSO4), filtered and the sol-
vent was evaporated to yield the target compounds as white
solids
1-((2-Benzhydryloxy)ethyl)piperazine (5): (853 mg, 53%):
1H NMR
(500 MHz, CDCl3): d=1.7 (NH), 2.5 (m, 4H), 2.7 (t, J=10.1 Hz, 2H),
2.9 (t, J=7.3 Hz, 4H), 3.65 (t, J=7.3 Hz, 2H), 7.26 (t, J=8.1 Hz, 1H),
7.33 (d, J=8.1 Hz, 1H), 7.36 ppm (t, J=8.1 Hz, 1H);
13C NMR
(125 MHz, CDCl3): d=46.2, 55.2, 59.0, 67.0, 84.1, 127.2, 127.8,
128.9 ppm; MS (ES, 50 eV): m/z (%): 296.2 (100), 297.2 (21) [M+H]
+;
HRMS-ES: m/z [M+H]
+ calcd for C19H24N2O: 297.18886, found:
297.18496.
1-[2-(10,11-Dihydro-5H-dibenzoACHTUNGTRENNUNG[a,d]cyclohepten-5-yloxy)ethyl]-
piperazine (6): (578 mg, 33%):
1H NMR (500 MHz, CDCl3): d=2.45
(m, 4H), 2.65 (t, J=10.1 Hz, 2H), 3.03 (q, J=12.9 Hz, 2H), 3.55 (q,
J=12.9 Hz, 2H), 3.60 (t, J=7.3 Hz, 2H) 5.40 (s, 1H), 7.15 (t, J=
7.6 Hz, 1H), 7.20 (t, J=7.6 Hz, 1H), 7.38 ppm (d, J=7.6 Hz, 1H);
13C NMR (125 MHz, CDCl3): d=32.1, 46.1, 55.0, 58.8, 66.3, 68.5,
125.6, 128.1, 129.1, 130.5, 132.9, 136.5 ppm; MS (ES, 50 eV): m/z
(%): 322.2 (100), 323.2 (23) [M+H]
+; HRMS-ES: m/z [M+H]
+ calcd
for C21H26N2O: 323.20451, found: 323.20477.
General procedure for synthesis of the N,N-disubstituted pipera-
zines (7 and 8): A solution of 3 or 4 (1 g, 3.68 mmol), substituted
piperazine (3.7 mmol) and K2CO3 (0.51 g, 3.7 mmol) in toluene
(6 mL) was heated under reflux for 16 h, cooled to RT, washed with
H2O (2 25 mL) and extracted with toluene (3 25 mL). After
column chromatography (silical gel, MeOH) the products were iso-
lated as white solids.
(1-[2-(10,11-Dihydro-5H-dibenzoACHTUNGTRENNUNG[a,d]cyclohepten-5-yloxy)ethyl]-
4-(3-phenyl-propyl)piperazine (7): (185 mg, 11%):
1H NMR
(500 MHz, CDCl3): d=1.85 (q, J=7.3 Hz, 2H), 2.4 (t, J=7.3 Hz, 2H),
2.5 (m, 8H), 2.63 (t, J=7.3 Hz, 2H), 2.68 (t, J=7.2 Hz, 2H), 3.01 (q,
J=12.8 Hz, 2H), 3.55 (q, J=12.8 Hz, 2H), 3.6 (t, J=7.2 Hz, 2H) 5.4
(s, 1H) 7.1–7.4 ppm (m, 13H);
13C NMR (125 MHz, CDCl3): d=28.3,
32.3, 33.8, 53.2, 53.7, 57.8, 58.0, 66.7, 125.9, 126.0, 126.8, 127.0,
127.1, 130.1, 130.2, 132.9, 135.2, 136.5 ppm; MS (ES, 50 eV): m/z
(%): 463.3 (100), 464.3 (33) [M+Na]
+; HRMS-ES: m/z [M+Na]
+ calcd
for C30H36N2O: 463.27253, found: 463.27123.
1-[2-(10,11-Dihydro-5H-dibenzoACHTUNGTRENNUNG[a,d]cyclohepten-5-yloxy)ethyl]-
4-(E)-3-phenyl-allyl)piperazine (8): (297 mg, 18%):
1H NMR
(500 MHz, CDCl3): d=2.53 (m, 8H), 2.65 (t, J=7.3 Hz, 2H), 3.0 (q,
J=7.3 Hz, 2H), 3.2 (d, J=7.8 Hz, 2H), 3.55 (q, J=12.7 Hz, 2H), 3.6
(t, J=12.7 Hz, 2H), 5.4 (s, 1H), 6.3 (t, J=15.9 Hz, 1H), 6.55 (d, J=
15.9 Hz, 1H), 7.1–7.4 ppm (m, 13H);
13C NMR (125 MHz, CDCl3): d=
32.2, 53.1, 53.4, 58.0, 60.8, 66.6, 68.5, 125.9, 126.4, 126.6, 127.5,
128.0, 128.6, 128.7, 130.3, 132.9, 133.1, 135.2, 136.5 ppm; MS (ES,
50 eV): m/z (%): 461.3 (100), 462.3 (32) [M+Na]
+; HRMS-ES: m/z
[M+Na]
+ calcd for C30H34N2O: 461.25688, found: 461.27478.
2-Chloro-10-(3-(4-(3-phenylpropyl)piperazin-1-yl)propyl)-10H-
phenothiazine (9): A mixture of 2-chlorophenothiazine (1.17 g,
5 mmol) and powdered KOH (0.29 g, 5 mmol) in dry DMF (10 mL)
was stirred under N2 for 30 min. The alkyl bromide 1,3-dibromo-
propane (3.03 g, 15 mmol) was introduced and the mixture was
stirred for 48 h at RT. The mixture was poured into H2O (50 mL)
and extracted with CH2Cl2, washed with H2O (2 50 mL), separated
and dried (MgSO4). After removal of the solvent, the crude product
was redissolved in toluene (10 mL) and treated with 1-(3-phenyl-
propyl)piperazine (1.02 g, 5 mmol) and K2CO3 (0.69 g, 5 mmol). The
reaction was heated under reflux for 48 h, cooled to RT, washed
with H2O (2 25 mL) and extracted with toluene (3 25 mL). After
column chromatography the product was isolated as a white solid
(120.4 mg; 5%):
1H NMR (500 MHz, [D6]DMSO): d=1.69 (p, J=
7.3 Hz, 2H), 1.97 (p, J=7.5 Hz, 2H), 2.26 (t, J=7.3 Hz, 4H), 2.51 (d,
J=8.1 Hz, 8H), 2.79 (t, J=7.3 Hz, 2H), 3.72 (t, J=7.5 Hz, 2H), 6.73
(d, J=7.4 Hz, 1H), 6.75 (d, J=7.4 Hz, 1H), 6.77 (t, J=7.4 Hz, 1H),
6.79 (t, J=7.4 Hz, 1H), 6.90 (d, J=7.4 Hz, 1H), 6.91 (d, J=7.6 Hz,
1H), 6.99 (t, J=7.6 Hz, 1H), 7.15 (t, J=7.6 Hz, 1H), 7.18 (d, J=
7.6 Hz, 2H), 7.25 ppm (t, J=7.6 Hz, 2H);
13C NMR (125 MHz,
[D6]DMSO): d=28.4, 32.0, 33.3, 37.4, 43.0, 44.9, 52.7, 57.9, 114.1,
114.2, 115.1, 115.2, 121.6, 122.8, 126.1, 126.7, 127.9, 128.2, 128.7,
128.7, 145.1, 146.8 ppm; MS (ES, 50 eV): m/z (%): 500.2 (100), 502.2
(32) [M+Na]
+; HRMS-ES: m/z [M+Na]
+ calcd for C28H32ClN3S:
500.19032, found: 500.18676.
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